OTC Supplemental Warning Regs Need Not Show Causation – FDA’s Troy
This article was originally published in The Tan Sheet
Executive Summary
FDA does not have to prove causality in order to require new warnings in the labeling of OTC drugs, Chief Counsel Daniel Troy clarified at the Generic Pharmaceutical Association's legal symposium in Washington, D.C. May 16
You may also be interested in...
Reye’s Syndrome Warning Will Not Apply To Salicylate Inactive Ingredients
OTC drugs containing salicylates as inactive ingredients will not be required to carry a Reye's syndrome warning in their labeling, according to a final rule published in the April 17 Federal Register
Diphenhydramine Poison Ivy Caution Not Required On External Analgesics
Topical diphenhydramine products will not be required to carry warnings against use on poison ivy, sunburns and broken skin under an FDA 1final rule published in the Federal Register Dec. 6
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC